Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing
Executive Summary
Recently introduced follow-on biologics legislation has several characteristics that make it distinct from the current approval pathway for generic drug
You may also be interested in...
FDA Follow-On Biologics Letter Creates Hurdle For Obama Administration
A letter from FDA to the House Energy & Commerce Committee could delay any plans the incoming Obama Administration may have in moving forward with an abbreviated pathway to approve follow-on biologics
FDA Follow-On Biologics Letter Creates Hurdle For Obama Administration
A letter from FDA to the House Energy & Commerce Committee could delay any plans the incoming Obama Administration may have in moving forward with an abbreviated pathway to approve follow-on biologics
Follow-On Biologics Bill Could Be Shaped By Waxman/Dingell Fight For House Commerce Cmte.
Chairmanship would give Waxman more leverage to place regulatory flexibility into the biosimilars approval pathway.